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Abstract
Background: To improve the diagnosis of tuberculosis (TB), more rapid diagnostic techniques such as antibody
detection based on immunochromatographic methods were developed. The objective of this study was to
evaluate the performance of the SD Rapid TB kit for the diagnosis of active TB with serums from patients and close
contact controls in Antananarivo, Madagascar.
Findings: We conducted a population-based case-control study. The sera of 60 confirmed TB patients and 60
healthy contacts paired for sex and age were tested. The controls were healthy contacts who were exposed to TB
but had no clinical or radiological evidence of TB. The SD Rapid TB kit was used with serum samples according to
the instructions of the manufacturer. Sensitivity, specificity, accuracy and predictive values were calculated using
culture on Lövenstein-Jensen media as “gold standard”.
In this study, the sensitivity of the test was 55% and the specificity 90%. The positive predictive value and the
negative predictive value were 84.61% and 66.66%, respectively, for diagnosis of pulmonary TB.
Conclusions: This study shows that the SD Rapid TB test is a simple and fast method. This test has a good
specificity and could therefore help rule in TB if positive, but lacks adequate sensitivity.
Background
Tuberculosis (TB) poses a significant health threat world-
wide with an estimated 9 million new cases and 2 million
deaths every year worldwide [1]. Morbidity associated with
TB has been decreasing but Human Immunodeficiency
Virus (HIV) associated TB and multidrug resistant (MDR)
are on the rise [2]. According to the 2010 World Health
Organization (WHO) report [1], the incidence of TB in
Madagascar is estimated at 248 per 100 000 population for
all forms of TB and 111/100 000 for smear-positive
pulmonary TB. The prevalence of TB is estimated at 415/
100 000 and the rate of human immunodeficiency virus
(HIV) infection among TB patients at 0.4%.
The vast majority of TB patients live in developing
countries, where the diagnosis of TB relies on the iden-
tification of acid-fast bacilli on unprocessed sputum
smears using conventional light microscopy. However,
40 to 60% of patients with pulmonary disease and ~75%
of patients with extrapulmonary disease are smear nega-
tive, and in this situation even contemporary culture
methods take several weeks to become positive [3].
Rapid diagnostic tests for TB are needed to facilitate
early treatment of TB and prevention of Mycobacterium
tuberculosis transmission. Therefore, a number of alterna-
tive diagnostic tests that use molecular, chromatographic
and immunological methods have been developed.
In this report, we evaluate an immunochromatographic
test (ICT) kit, SD BioLINE Rapid TB
® which can detect
serum antibodies directed against specific recombinant
antigens of M. tuberculosis for the diagnosis of pulmon-
ary TB, by determining its sensitivity and specificity as
compared to standard diagnostic procedures in Antana-
narivo, Madagascar.
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Patients
This study was designed as a pair matching case-control
study. Between October 2007 and December 2008, 60
newly recruited sputum-positive TB patients (cases) over
15 years of age were enrolled at the principal anti-TB
center of Antananarivo, the capital of Madagascar, where
the annual incidence of newly diagnosed sputum smear-
positive patients is about 80 cases per 100, 000 inhabi-
tants according to the National TB Control Programme
(NTCP) [4]. The patients were treated according to the
NTCP strategy and were followed up by the clinical
physicians.
The 60 subjects selected for the patients group had a
median age of 35.5 years (age range, 15-59 years) and
54 (45%) were males, 66 (55%) were females.
Control group
The control group consisted of 60 individuals selected
randomly from apparently healthy household or family
contacts of TB patients, and matched for sex and age
with case subjects (difference between birthdays less than
5 years). All members of control group had no previous
h i s t o r yo fT B ,n os i g n so rs y m p t o m ss u g g e s t i v eo fp u l -
monary TB, no evidence of TB on chest X rays. The
household contacts (HCs) of the included index cases
w e r ev i s i t e da th o m eb yt h es t u d yp h y s i c i a n sa n dw e r e
invited to join the study. They were included if they were
≥15 year old and had been living in the same house as
the case patient for at least 6 months.
Household contacts controls underwent a PPD skin
test (10 units; tuberculin purified protein derivative;
Aventis Pasteur). Induration was recorded after 72 h.
All subjects selected for the control group were HIV
and PPD skin test negative.
Serum samples were obtained from almost all patients
before initiation of antituberculosis treatment and stored
at -20°C until tested. All patients and controls participated
in the study were vaccinated with Mycobacterium bovis
BCG. Individuals with a diagnosis of TB disease were
referred to the antituberculosis center for treatment.
T h es t u d yw a sa p p r o v e db yt h eN a t i o n a lE t h i c sC o m -
mittee to the Ministry of Health in Madagascar.
Samples collection
All TB cases were screened for TB independently by
microscopy, culture and SD Rapid TB to evaluate the per-
formance of the test under field conditions. A question-
naire was filled for each patient with basic clinical and
demographic information after taking written consent.
Three sputum samples were obtained from each of the 60
patients using routine techniques, and the samples were
processed in the Chest Clinic according to established
n o r m s[ 5 ] .V e n o u sb l o o dw a sd r a w nf r o mt h es t u d y
participants and placed into one 5 ml dry vacutainer tube
without preservative or anticoagulant for separation of
serum. Each serum sample was divided into two parts:
part was used for HIV testing and the other was frozen at
-20°C for SD Rapid TB testing.
SD Rapid TB interpretation
The SD Rapid TB test (Standard Diagnostic, Inc; Cat. No.
08FK10) is a chromatographic immunoassay for qualita-
tive detection of antibodies to M. tuberculosis in human
serum. Briefly, the test consists of a cardboard folding
device containing a nitrocellulose strip and absorbent
pads. Antigen secreted by M. tuberculosis during active
infection is immobilized on a line across the strip. When
serum (100 μl) is applied, it flows past the antigen line. If
specific antibody to the antigen is present, it binds to the
line. Bound antibody is detected by a goat anti-human
immunoglobulin G antibody conjugated to colloidal gold
particles which give a pink band when bound to human
antibody. Test card has one control line to indicate the
validity of the test procedure and its working condition.
Control and test lines appeared within 15 minutes in a
reading window. SD Rapid TB was performed and the
results were interpreted according to the instructions of
the manufacturer by two independent readers who were
blind to the clinical status of the subjects and to the TB
diagnosis results. The presence of two bands (control and
test line) indicates a positive result (Figure 1). Each SD
Rapid TB was saved as documentation for future refer-
ence. Only tests from one batch were used (Manufacture
June 07, expiry January 09 batch no. 046022).
Clinical and laboratory evaluation
Two spot and one overnight sputum specimens were
collected from each patient.
The sputa were decontaminated by the sodium dodecyl
sulfate method of Tacquet and Tison [5]. Fluorescence
microscopy was performed for the direct detection of
mycobacteria by the auramine staining method [6]. One
drop of the decontaminated sputum was fixed on a slide,
stained with auramine-phenol, and examined under a
fluorescence microscope (objective, ×40) for acid-fast
bacilli (AFB). Sputum smear microscopy was considered
positive when AFB were seen in at least two out of the
three specimens. The remaining decontaminated speci-
men was inoculated into two tubes of standard LJ med-
ium (Diagnostics Pasteur, Paris, France) and on one tube
of LJ medium without glycerol but supplemented with
0.5% pyruvate. Culture said to be positive when at least
one colony of M. tuberculosis was grown, and negative if
there was no growth after 8 week. The numbers of colony
forming unit (CFU) growing in each LJ tube were
counted. Mycobacterial isolates were identified according
to growth on LJ medium, colony morphology, and
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catalase, urease, and nitrate reductase [6]. All subjects
included were serotested for HIV.
Data analysis
The performance of SD Rapid TB was expressed by cal-
culating the sensitivity, specificity, positive predictive
values (PPV) and negative predictive values (NPV) for
TB separately taking culture results as gold standard
(According to Grange and Laszlo 1990 [7]). Data were
double entered, validated and analysed using Epi Info™
3.3.6 software (CDC Atlanta GA, USA). Proportions
were compared using the chi-square test.
Results
T h es e r u ms a m p l e si n c l u d e di nt h es t u d yw e r ef r o m
patients in whom the disease had been confirmed by iso-
lation of the tubercle bacillus on culture (LJ). Sera were
also collected from 263 contacts of TB patients. After
matching for sex and age, 120 individuals were selected
and enrolled (60 cases/60 age and sex-matched control
subjects). All subjects were Malagasy and HIV negative.
None of the control subjects became ill during the 1 year
follow-up. No samples gave indeterminate results with
the SD Rapid TB test. Of the 60 AFB smear-positive and
culture-positive patients evaluated, 33 (55%, 95%CI:
[0.425 to 0.669]) were positive with the SD Rapid TB test.
Positive results were also obtained for six (10%) of the 60
apparently healthy contacts, so the specificity of the test
w a s9 0 % ,9 5 % C I :[ 0 . 7 9 9t o0 . 9 5 3 ] .T h e r ew a sas t a t i s t i -
cally significant difference between the results obtained
with the SD Rapid TB test and culture (McNemar test,
P < 0.0001). The difference between ICT results in pul-
monary TB patients and control subjects was statistically
significant (P < 0.0001). The PPV and NPV of the SD
Rapid TB were 84.62% and 66.67% respectively.
Discussion
TB is a major public health problem throughout the
world, particularly in developing country. Lack of sensi-
tivity in smear examination, non-specificity of radiologi-
cal findings, and extended turn around time of
M. tuberculosis culture have necessitated exploring the
utility of serodiagnostic of TB. TB serology based on
Figure 1 Interpretation of SD Rapid TB results. (A) Sample insertion. (B) Test result. (C) Internal control; 1. Negative result; 2. Positive result.
When serum or plasma applied (A), it flows past the antigen line (B). Bound antibody is detected by a goat anti-human IgG antibody
conjugated to colloidal gold particles which produces one pink line when bound to human antibody. The test is considered positive when at
least the antigen line and the control line (C) develop a pink color.
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itoring tubercular infection with low cost and flexibility
to adapt to small laboratories may be a tremendous
advantage to the developing countries. A number of ser-
ologic tests were developed for detection of antibody
against to M. tuberculosis, but none of them has found
widespread clinical use [8].
This study was designed to evaluate the diagnostic
potential of SD BioLINE Rapid TB
® test for the detection
of TB. We found that the specificity (90%) was similar to
the results for adult ICT-TB reported by other authors
(between 88% and 95%) [8,9]. We also found that the sen-
sitivity was low (55%). Similarly performance has pre-
viously been reported for other serological tests to identify
pulmonary TB patients, in particular, sensitivity is poor to
moderate (16% to 57%) for seven serological tests, includ-
ing two immunochromatographic tests (ICT Tuberculosis
and RAPID TEST TB) and five enzyme-linked immuno-
sorbent assays (TUBERCULOSIS IgA enzyme immunoas-
say, PATHOZYME-TB complex, PATHOZYME-MYCO
IgG, PATHOZYME-MYCO IgA, and PATHOZYME-
MYCO IgM) [10].
Discrepancies between studies in the results of a com-
mercially available serological test can most often be
attributed to differences in the populations studied.
The performance of the rapid test kit as concerns sensi-
tivity, by comparison with direct sputum smear micro-
scopy and culture, was unsatisfactory. The low sensitivity
of this assay seems to be because the antibody response to
a particular antigen may not be universal, as established by
Lyashchenko et al. [11].
The first antigen used in this assay is a highly specific
recombinant 38 kDa antigen from M. tuberculosis which
has been produced and purified from Escherichia coli[12].
This antigen has been reported to be the single most
important antigen for the serodiagnosis of TB [13]. The
16-kDa antigen (second antigen) is reported to be a pro-
minent antigen of M. tuberculosis, with epitopes restricted
to M. tuberculosis complex based on B-cell recognition
[14]. ESAT-6 was characterized and purified in 1995 by
Sorensen et al. [15], and has since been used in various
studies as an antigen with diagnostic potential: It was
found to be specific for M. tuberculosis and absent from
M. bovis BCG and most environmental mycobacteria.
This new test detects IgA antibodies in serum. An
increase in circulating IgA has been found in TB patients,
but also in sera from both patients with other infectious
respiratory diseases and patients with rheumatic and auto-
immune diseases and persistent infections [16-19] Thus,
the detection of IgA may increase the sensitivity of the
detection of pulmonary TB, but it may also be the cause of
the false-positive results obtained in the group of non-TB
patients.
Diagnostic tests provide information that guides health
care providers’ decisions about initiating therapy. How-
ever, the efficacy of diagnostic tests depends on charac-
teristics of the population. The prevalence of a disease is
a well-known and powerful determinant of how useful
for the clinician a diagnostic test for the disease will be.
Its consequences for diagnostic test performance (e.g.t h e
probability of a positive/negative result) are taken into
account through the positive and negative predictive
values. Indeed, the diagnostic value of a given test in clin-
ical practice depends on its positive and negative predic-
tive values, and these values vary markedly with the
prevalence of the disease in the relevant community [20].
We calculated PPVs and NPVs using in several hypothe-
tical pre-test probability estimates. The utility of the SD
Rapid TB kit as a diagnostic test in a group of patients
with TB, with pre-test probability of TB hypothesized
from 10% to 100% showed that the cut-off value for the
SD Rapid TB kit for best sensitivity and specificity was in
the range of TB prevalence between 35% and 45%. How-
ever, our study also had limitations on the estimation of
diagnostic accuracy generated by using cases and con-
trols study [21]. Often, mild cases that are difficult to
diagnose are omitted from case-control studies, causing
an overestimation of sensitivity as well as specificity.
This study, although limited by the small number of
volunteers, highlights the validity of the new ICT for
detection of TB in endemic area.
The sensitivity is low as compared to other studies due
to the reason that some people show poor antibody pro-
duction due to genetic variations and differences in study
populations [22]. One of the major problems in the sero-
diagnosis of TB has been heterologous antibody responses
to various M. tuberculosis antigens. It seems, therefore,
that more than one antigen is required for increased sensi-
tivity. This approach may result in a lower specificity
despite the use of M. tuberculosis specific antigens. Thus,
performance of this ICT can be improved by using more
purified specific antigens and the usefulness of the test
should be investigated greater in endemic areas. Data
obtained in this study on the quality of antibody response
in the ICT positive samples, might be used to improve the
performance of the test.
Conclusions
In conclusion, the test cannot be used as a replacement for
smear microscopy for the diagnosis of pulmonary TB
because of its poor sensitivity. However, it may be worth
assessing this kit, in future investigations, for the detection
of extrapulmonary TB or pediatric TB, that is situation in
which bacteriologic confirmation is often difficult [23,24].
Otherwise, the SD BioLINE Rapid TB
® kit, with its accep-
table specificity, and despite inadequate sensitivity, could
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where the prevalence is between 35% and 45%. A better
understanding of antibody responses in TB patients may
facilitate the development of more sensitive and specific
antibody-based methods for the TB diagnosis.
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